Evidence map›Paper›PMID 23893900›Full record

ArticlePharmaceutical statistics

Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.

Anastasia Ivanova, Changfu Xiao

Abstract readComparative Study
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anastasia IvanovaDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Changfu Xiao

Funding

Current Design Issues in Oncology TrialsR01CA120082 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IVANOVA, ANASTASIA · 2006 to 2008
$403k
NCI NIH HHS R01 CA120082NCI NIH HHS R01 CA120082-01A1
6 · The paper itself

Abstract

Consider the problem of estimating a dose with a certain response rate. Many multistage dose-finding designs for this problem were originally developed for oncology studies where the mean dose-response is strictly increasing in dose. In non-oncology phase II dose-finding studies, the dose-response curve often plateaus in the range of interest, and there are several doses with the mean response equal to the target. In this case, it is usually of interest to find the lowest of these doses because higher doses might have higher adverse event rates. It is often desirable to compare the response rate at the estimated target dose with a placebo and/or active control. We investigate which of the several known dose-finding methods developed for oncology phase I trials is the most suitable when the dose-response curve plateaus. Some of the designs tend to spread the allocation among the doses on the plateau. Others, such as the continual reassessment method and the t-statistic design, concentrate allocation at one of the doses with the t-statistic design selecting the lowest dose on the plateau more frequently.

Indexed as

Dose-Response Relationship, DrugClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicCohort StudiesDrug Delivery SystemsHumansResearch Designcontinual reassessment methodgroup up-and-down designsphase II trialsproof of conceptt-statistic design

Identifiers

PMID23893900
PMCPMC3770738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.